Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.71 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865780 | 0.91 | MLYCD (0.77) | MLYCDNAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL12243059 | 0.84 | MLYCD (0.69) | MLYCDNPC1RAB9AHDAC6KMT2A | |
| SCHEMBL5687748 | 0.84 | MLYCD (0.69) | MLYCDNAMPTNPC1RAB9AHDAC6 | |
| SCHEMBL8270501 | 0.83 | HDAC3 (0.65) | MLYCDSSTR3HDAC6ALDH1A1 | |
| SCHEMBL19938019 | 0.83 | MLYCD (0.67) | MLYCDNAMPTNPC1RAB9AHDAC6 | |
| SCHEMBL20868189 | 0.83 | MLYCD (0.62) | MLYCDNAMPTSSTR3KMT2AMEN1 | |
| SCHEMBL10224050 | 0.82 | MLYCD (0.66) | MLYCDNAMPTNPC1RAB9APOLB | |
| SCHEMBL3669916 | 0.82 | HDAC4 (0.53) | MLYCDHDAC6 | |
| SCHEMBL9784573 | 0.81 | MLYCD (0.65) | MLYCDNAMPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL8349985 | 0.80 | ALDH1A1 (0.73) | NAMPTNPC1RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
| WO-1998037068-A1 | BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | MLYCD 2637/4885NAMPT 559/4885SSTR3 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.